MK-1084 Market Summary

Key Factors Driving MK-1084 Growth

1. Strong first-line NSCLC activity with pembrolizumab is the key growth driver: The most compelling opportunity is MK-1084 + KEYTRUDA in previously untreated metastatic NSCLC. In the Phase I KANDLELIT-001 study, the combination produced a 77% confirmed ORR among 69 patients with KRAS G12C-mutated NSCLC and PD-L1 TPS ≥1%; ORR was 88% in patients with PD-L1 TPS ≥50%. The disease-control rate was 96%, and median duration of response had not been reached at the data cutoff. These results have supported the move into Phase III development.

2. FDA Breakthrough Therapy designation validates the first-line opportunity: In May 2026, the FDA granted MK-1084 Breakthrough Therapy designation in combination with pembrolizumab for first-line treatment of advanced/metastatic KRAS G12C-mutated NSCLC with PD-L1 TPS ≥1%. Merck noted that the designation was supported by positive KANDLELIT-001 data. Breakthrough Therapy status can facilitate regulatory interactions and potentially accelerate development/review, increasing the probability of earlier commercialization if pivotal trials succeed.

3. Large KRAS G12C-positive NSCLC population provides a sizeable commercial opportunity: Merck estimates that KRAS G12C occurs in approximately 14% of NSCLC adenocarcinomas. This makes it a substantially larger molecular target than many rare oncogenic alterations. Importantly, MK-1084 is being developed not only for previously treated disease but also for first-line treatment, potentially allowing it to capture patients earlier in their treatment journey and generate longer treatment exposure.

4. Promising activity in previously treated NSCLC supports a broader treatment franchise: MK-1084 monotherapy produced a 38% ORR and 76% disease-control rate in previously treated KRAS G12C-mutated NSCLC in KANDLELIT-001, with median PFS of approximately 8 months in the reported dataset. This provides a second potential treatment setting in addition to first-line combination therapy and supports development across multiple lines of therapy.

5. CRC expansion could create a second major commercial indication: KRAS G12C-mutated CRC represents another important opportunity. In KANDLELIT-001, MK-1084 monotherapy produced a 38% confirmed ORR, while MK-1084 + cetuximab produced a 46% ORR and 92% disease-control rate. The triplet of MK-1084 + cetuximab + mFOLFOX6 generated a 38% confirmed ORR overall and 58% in patients receiving it as first-line therapy. Merck has subsequently initiated KANDLELIT-012, a Phase III trial evaluating MK-1084 + cetuximab + mFOLFOX6 with/without bevacizumab in KRAS G12C-mutated mCRC; the randomized portion is planned to enroll approximately 462 patients.

6. Broad development strategy increases lifecycle potential: Merck is building MK-1084 as a multi-tumor, multi-setting KRAS G12C franchise, rather than pursuing only one indication. The KANDLELIT program includes Phase III studies in first-line NSCLC and CRC, while a tumor-agnostic Phase II study (KANDLELIT-014) is also recruiting patients with KRAS G12C-mutated advanced solid tumors. In addition, KANDLELIT-007 is evaluating MK-1084 + subcutaneous KEYTRUDA QLEX in approximately 675 newly diagnosed patients with nonsquamous advanced/metastatic NSCLC. This breadth creates multiple potential routes to commercialization and lifecycle expansion.

MK-1084 Recent Developments

In January 2026, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the initiation of KANDLELIT-007, a Phase III clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

“MK-1084 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of MK-1084 for potential indication like Adenocarcinoma, Non-small cell lung cancer, and Solid tumours in the 7MM. A detailed picture of MK-1084’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the MK-1084 for potential indications. The MK-1084 market report provides insights about MK-1084’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current MK-1084 performance, future market assessments inclusive of the MK-1084 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of MK-1084 sales forecasts, along with factors driving its market.

MK-1084 Drug Summary

MK-1084, now known as Calderasib, is an investigational, orally administered, potent and highly selective next-generation covalent inhibitor of the KRAS G12C mutant protein, being developed by Merck in collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals for the treatment of KRAS G12C-mutated solid tumors, particularly non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). By selectively binding to KRAS G12C and inhibiting KRAS-mediated signaling, calderasib is designed to suppress tumor-cell proliferation and survival. The drug is administered orally, with clinical studies evaluating once-daily dosing as monotherapy and in combination with pembrolizumab, cetuximab, and chemotherapy. In the Phase 1 KANDLELIT-001 study, MK-1084 demonstrated encouraging antitumor activity, including a confirmed objective response rate of 38% as monotherapy in previously treated KRAS G12C-mutated CRC and 38% as monotherapy in previously treated NSCLC; in previously untreated metastatic NSCLC, the combination of MK-1084 and pembrolizumab produced an objective response rate of 77% in patients with PD-L1 TPS ≥1%. As of 2026, calderasib remains investigational and is being evaluated in multiple Phase 3 studies, including KANDLELIT-004 and KANDLELIT-007 in first-line KRAS G12C-mutated NSCLC and KANDLELIT-012 in CRC. The FDA granted Breakthrough Therapy designation in May 2026 for calderasib in combination with pembrolizumab for certain patients with newly diagnosed advanced or metastatic KRAS G12C-mutated NSCLC expressing PD-L1 TPS ≥1%. The report provides MK-1084’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the MK-1084 Market Report

The report provides insights into:

• A comprehensive product overview including the MK-1084 MoA, description, dosage and administration, research and development activities in potential indication like Adenocarcinoma, Non-small cell lung cancer, and Solid tumours.
• Elaborated details on MK-1084 regulatory milestones and other development activities have been provided in MK-1084 market report.
• The report also highlights MK-1084‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The MK-1084 market report also covers the patents information, generic entry and impact on cost cut.
• The MK-1084 market report contains current and forecasted MK-1084 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The MK-1084 market report also features the SWOT analysis with analyst views for MK-1084 in potential indications.

Methodology

The MK-1084 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MK-1084 Analytical Perspective by DelveInsight

• In-depth MK-1084 Market Assessment

This MK-1084 sales market forecast report provides a detailed market assessment of MK-1084 for potential indication like Adenocarcinoma, Non-small cell lung cancer, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted MK-1084 sales data uptil 2034.

• MK-1084 Clinical Assessment

The MK-1084 market report provides the clinical trials information of MK-1084 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

MK-1084 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

MK-1084 Market Potential & Revenue Forecast

• Projected market size for the MK-1084 and its key indications
• Estimated MK-1084 sales potential (MK-1084 peak sales forecasts)
• MK-1084 Pricing strategies and reimbursement landscape

MK-1084 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• MK-1084 Market positioning compared to existing treatments
• MK-1084 Strengths & weaknesses relative to competitors

MK-1084 Regulatory & Commercial Milestones

• MK-1084 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

MK-1084 Clinical Differentiation

• MK-1084 Efficacy & safety advantages over existing drugs
• MK-1084 Unique selling points

MK-1084 Market Report Highlights

• In the coming years, the MK-1084 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The MK-1084 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MK-1084’s dominance.
• Other emerging products for Adenocarcinoma, Non-small cell lung cancer, and Solid tumours are expected to give tough market competition to MK-1084 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MK-1084 in potential indications.
• Analyse MK-1084 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted MK-1084 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of MK-1084 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of MK-1084? How strong is MK-1084’s clinical and commercial performance?
• What is MK-1084’s clinical trial status in each individual indications such as Adenocarcinoma, Non-small cell lung cancer, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MK-1084 Manufacturers?
• What are the key designations that have been granted to MK-1084 for potential indications? How are they going to impact MK-1084’s penetration in various geographies?
• What is the current and forecasted MK-1084 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of MK-1084 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MK-1084 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is MK-1084? What is the duration of therapy and what are the geographical variations in cost per patient?